menu

Understanding the Biological and Clinical Rationale for PARP Inhibitor Combinations as Potential Treatment for Prostate Cancer

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Understanding the Biological and Clinical Rationale for PARP Inhibitor Combinations as Potential Treatment for Prostate Cancer

1.00 credits
60 minutes

CME/CE Broadcast Replay

ReachMD Healthcare Image
Restart
Resume
Choose a format
Take Post-TestSkip straight to the post-test if you have already participated in this activity
Media formats available:
1.00 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Comments
  • Overview

    Prostate cancer is a disease characterized by high genomic instability. Prostate cancers with deleterious aberrations in DNA damage repair (DDR) genes, including homologous recombination repair (HRR), such as mutations in BRCA1/2 and ATM, are associated with response to poly(adenosine diphosphate–ribose) polymerase (PARP) inhibition. The US Food and Drug Administration (FDA) has approved PARP inhibitors as monotherapy for the treatment of previously treated patients with HRR gene-mutated (olaparib) and BRCA mutation-associated (rucaparib) metastatic castration-resistant prostate cancer (mCRPC). Despite the advances with PARP inhibitors as monotherapy, primary and secondary resistances are seen, and evidence suggests that PARP inhibitors should be reserved for mCRPC with BRCA1, BRCA2, or ATM mutations. Now, clinical trials are evaluating PARP inhibitors in combination with other treatments such as androgen pathway inhibitors which may expand the clinical use of PARP inhibitors. When PARP inhibition is combined with novel hormonal therapies, a treatment benefit may be observed regardless of the HRR deficiency status.

    This educational activity will review emerging clinical evidence and potentially practice-changing advancements in the treatment of mCRPC with PARP inhibitor combination treatment strategies, especially those that include combinations with androgen receptor targeted agents, to improve understanding of the evolving treatment and management of mCRPC.

  • Disclosure of Relevant Financial Relationships

    AXIS Medical Education requires faculty, instructors, authors, planners, directors, managers, reviewers, and other individuals who are in a position to control the content of this activity to disclose all real or apparent conflicts of interest they may have with ineligible companies. An ineligible entity is any organization whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant conflicts of interest are identified and mitigated prior to initiation of the planning phase for an  activity. 

    AXIS has mitigated and disclosed to learners all relevant conflicts of interest disclosed by staff, planners, faculty/authors, peer reviewers, or others in control of content for this activity. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation or activity. Disclosure information for faculty, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.

    The faculty reported the following relevant financial relationships or relationships they have with ineligible companies of any amount during the past 24 months:

    Neeraj Agarwal, MD, FASCO, reported a financial interest/relationship or affiliation in the form of Research funding to Huntsman Cancer Institute; Arnivas, Astellas Pharma US, Inc., AstraZeneca Pharmaceuticals LP., Bayer Pharmaceuticals Corporation, Bristol-Myers Squibb Company, Calithera Biosciences Inc., Celldex, Inc., Clovis Oncology, Crispr, Eisai Inc., Eli Lilly and Company, EMD Serono, Inc., Exelixis, Inc., Genentech, Inc., Gilead, GlaxoSmithKline, Immunomedics, Inc., Janssen Oncology, Lava, Merck & Co, Inc., Nektar Pharmaceuticals Inc., Neoleukin, New Link Genetics, Novartis Pharmaceuticals Corporation, Oric, Pfizer, Inc, Prometheus, Rexahn, Roche, Sanofi, Seattle Genetics, Inc., Takeda Oncology & Tracon Pharmaceuticals, Inc.

    The directors, planners, managers, and reviewers reported the following financial relationships they have with any ineligible company of any amount during the past 24 months: Linda  Gracie-King, MS; Jocelyn Timko, BS; Marilyn L. Haas-Haseman, PhD, RN, CNS, ANP-BC; Adrienne N. Nedved, MPA, PharmD, BCOP; and Melissa Duffy, PA-C hereby state that they do not have any financial relationships or relationships with any ineligible company of any amount during the past 24 months.  Robert Mocharnuk, MD, reported a financial interest/relationship or affiliation in the form of Common stock: Merck of any amount during the past 24 months.

  • Target Audience

    This educational activity is designed for medical oncologists, urologists, pathologists, oncology/urology advanced practitioners (nurses, physician assistants, pharmacists) and other healthcare professionals who actively treat or manage prostate cancer.

  • Learning Objectives

    At the conclusion of this activity, participants should be better able to:

    • Describe the mechanism of action of PARP inhibitor combination treatment strategies in patients with mCRPC
    • Assess the rationale for combining PARP inhibitors with androgen receptor-targeted therapies for the treatment of patients with mCRPC
    • Evaluate recent and emerging clinical efficacy and safety data, and ongoing clinical trials of PARP inhibitor combinations in men with mCRPC with and without DDR defects
  • Accreditation and Credit Designation Statements

    Accreditation Statement

     

    In support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

     

     

    This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

     

     

     

     


    Credit Designation for Physicians

    AXIS Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     

    Credit Designation for Physician Assistants

    AXIS Medical Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits.  Approval is valid until June 20, 2024. PAs should only claim credit commensurate with the extent of their participation.

     

     

    Credit Designation for Pharmacists
    This application-based activity is approved for 1.0 contact hour of continuing pharmacy education JA4008106-0000-23-023-H01-P.

    Credit Designation for Nursing
    AXIS Medical Education designates this continuing nursing education activity for 1.0 contact hour.
    Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

     

  • Disclaimer

    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

  • Provider(s)/Educational Partner(s)

    Provided by AXIS Medical Education.

  • Commercial Support

    Supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

  • Method of Participation and Request for Credit

    To receive credit for this activity, participants must review the activity information including learning objectives and faculty/planner disclosures and actively participate in the educational activity. Upon successfully completing the post-test with a score of 75% or better and the post-activity evaluation, your certificate will be made available immediately. For pharmacists, your record will be uploaded to CPE Monitor.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Comments
  • Overview

    Prostate cancer is a disease characterized by high genomic instability. Prostate cancers with deleterious aberrations in DNA damage repair (DDR) genes, including homologous recombination repair (HRR), such as mutations in BRCA1/2 and ATM, are associated with response to poly(adenosine diphosphate–ribose) polymerase (PARP) inhibition. The US Food and Drug Administration (FDA) has approved PARP inhibitors as monotherapy for the treatment of previously treated patients with HRR gene-mutated (olaparib) and BRCA mutation-associated (rucaparib) metastatic castration-resistant prostate cancer (mCRPC). Despite the advances with PARP inhibitors as monotherapy, primary and secondary resistances are seen, and evidence suggests that PARP inhibitors should be reserved for mCRPC with BRCA1, BRCA2, or ATM mutations. Now, clinical trials are evaluating PARP inhibitors in combination with other treatments such as androgen pathway inhibitors which may expand the clinical use of PARP inhibitors. When PARP inhibition is combined with novel hormonal therapies, a treatment benefit may be observed regardless of the HRR deficiency status.

    This educational activity will review emerging clinical evidence and potentially practice-changing advancements in the treatment of mCRPC with PARP inhibitor combination treatment strategies, especially those that include combinations with androgen receptor targeted agents, to improve understanding of the evolving treatment and management of mCRPC.

  • Disclosure of Relevant Financial Relationships

    AXIS Medical Education requires faculty, instructors, authors, planners, directors, managers, reviewers, and other individuals who are in a position to control the content of this activity to disclose all real or apparent conflicts of interest they may have with ineligible companies. An ineligible entity is any organization whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant conflicts of interest are identified and mitigated prior to initiation of the planning phase for an  activity. 

    AXIS has mitigated and disclosed to learners all relevant conflicts of interest disclosed by staff, planners, faculty/authors, peer reviewers, or others in control of content for this activity. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation or activity. Disclosure information for faculty, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.

    The faculty reported the following relevant financial relationships or relationships they have with ineligible companies of any amount during the past 24 months:

    Neeraj Agarwal, MD, FASCO, reported a financial interest/relationship or affiliation in the form of Research funding to Huntsman Cancer Institute; Arnivas, Astellas Pharma US, Inc., AstraZeneca Pharmaceuticals LP., Bayer Pharmaceuticals Corporation, Bristol-Myers Squibb Company, Calithera Biosciences Inc., Celldex, Inc., Clovis Oncology, Crispr, Eisai Inc., Eli Lilly and Company, EMD Serono, Inc., Exelixis, Inc., Genentech, Inc., Gilead, GlaxoSmithKline, Immunomedics, Inc., Janssen Oncology, Lava, Merck & Co, Inc., Nektar Pharmaceuticals Inc., Neoleukin, New Link Genetics, Novartis Pharmaceuticals Corporation, Oric, Pfizer, Inc, Prometheus, Rexahn, Roche, Sanofi, Seattle Genetics, Inc., Takeda Oncology & Tracon Pharmaceuticals, Inc.

    The directors, planners, managers, and reviewers reported the following financial relationships they have with any ineligible company of any amount during the past 24 months: Linda  Gracie-King, MS; Jocelyn Timko, BS; Marilyn L. Haas-Haseman, PhD, RN, CNS, ANP-BC; Adrienne N. Nedved, MPA, PharmD, BCOP; and Melissa Duffy, PA-C hereby state that they do not have any financial relationships or relationships with any ineligible company of any amount during the past 24 months.  Robert Mocharnuk, MD, reported a financial interest/relationship or affiliation in the form of Common stock: Merck of any amount during the past 24 months.

  • Target Audience

    This educational activity is designed for medical oncologists, urologists, pathologists, oncology/urology advanced practitioners (nurses, physician assistants, pharmacists) and other healthcare professionals who actively treat or manage prostate cancer.

  • Learning Objectives

    At the conclusion of this activity, participants should be better able to:

    • Describe the mechanism of action of PARP inhibitor combination treatment strategies in patients with mCRPC
    • Assess the rationale for combining PARP inhibitors with androgen receptor-targeted therapies for the treatment of patients with mCRPC
    • Evaluate recent and emerging clinical efficacy and safety data, and ongoing clinical trials of PARP inhibitor combinations in men with mCRPC with and without DDR defects
  • Accreditation and Credit Designation Statements

    Accreditation Statement

     

    In support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

     

     

    This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

     

     

     

     


    Credit Designation for Physicians

    AXIS Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     

    Credit Designation for Physician Assistants

    AXIS Medical Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits.  Approval is valid until June 20, 2024. PAs should only claim credit commensurate with the extent of their participation.

     

     

    Credit Designation for Pharmacists
    This application-based activity is approved for 1.0 contact hour of continuing pharmacy education JA4008106-0000-23-023-H01-P.

    Credit Designation for Nursing
    AXIS Medical Education designates this continuing nursing education activity for 1.0 contact hour.
    Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

     

  • Disclaimer

    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

  • Provider(s)/Educational Partner(s)

    Provided by AXIS Medical Education.

  • Commercial Support

    Supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

  • Method of Participation and Request for Credit

    To receive credit for this activity, participants must review the activity information including learning objectives and faculty/planner disclosures and actively participate in the educational activity. Upon successfully completing the post-test with a score of 75% or better and the post-activity evaluation, your certificate will be made available immediately. For pharmacists, your record will be uploaded to CPE Monitor.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule25 Sep 2023